Loading
Showed that four cycles of cisplatin and vinorelbine after surgery for stage IB or II lung cancer lengthen life, and defined the regimen that became standard.
JBR.10 randomised 482 patients with completely resected stage IB or II non-small-cell lung cancer and an ECOG performance status of 0 or 1 to vinorelbine plus cisplatin (242 patients) or observation (240). Forty-five percent had stage IB disease and 55 percent stage II; the median age was 61 and 53 percent had adenocarcinoma.
Adjuvant chemotherapy prolonged both disease-free and overall survival. The cost was real: neutropenia in 88 percent, including grade 3 febrile neutropenia in 7 percent, two deaths from toxic effects (0.8 percent), fatigue in 81 percent, nausea in 80 percent, anorexia in 55 percent and neuropathy in 48 percent, though severe non-haematological effects were uncommon.
JBR.10 is why cisplatin with vinorelbine, rather than cisplatin with etoposide, became the adjuvant backbone, and its long-term follow-up showed the benefit was confined to stage II disease, which is why stage IB is now a discussion rather than a recommendation.
Shares ANITA (Adjuvant Navelbine International Trialist Association), Resectable stage I to III non-small-cell lung cancer, Lung cancer (all types).
Shares Vinorelbine, Resectable stage I to III non-small-cell lung cancer, Cisplatin, Platinum agents.
Shares Resectable stage I to III non-small-cell lung cancer, Cisplatin, Platinum agents, Cytotoxic chemotherapy.
Shares Resectable stage I to III non-small-cell lung cancer, Cisplatin, Platinum agents, Cytotoxic chemotherapy.
Shares Resectable stage I to III non-small-cell lung cancer, Cisplatin, Platinum agents, Cytotoxic chemotherapy.
Shares Resectable stage I to III non-small-cell lung cancer, Cisplatin, Platinum agents, Cytotoxic chemotherapy.
Shares Vinorelbine, Cisplatin, Lung cancer (all types).
Shares Vinorelbine, Resectable stage I to III non-small-cell lung cancer, Cisplatin, Platinum agents.